US20040185103A1 - Methods and compositions for enhanced delivery of bioactive molecules - Google Patents

Methods and compositions for enhanced delivery of bioactive molecules Download PDF

Info

Publication number
US20040185103A1
US20040185103A1 US10/766,106 US76610604A US2004185103A1 US 20040185103 A1 US20040185103 A1 US 20040185103A1 US 76610604 A US76610604 A US 76610604A US 2004185103 A1 US2004185103 A1 US 2004185103A1
Authority
US
United States
Prior art keywords
interferon
formulation
polymer
conjugate
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/766,106
Inventor
Danny Lewis
Paul Schmidt
Kenneth Hinds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PR Pharmaceuticals Inc
Surmodics Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/766,106 priority Critical patent/US20040185103A1/en
Publication of US20040185103A1 publication Critical patent/US20040185103A1/en
Assigned to SILICON VALLEY BANK reassignment SILICON VALLEY BANK SECURITY AGREEMENT Assignors: PR PHARMACEUTICALS, INC.
Priority to US12/186,203 priority patent/US20080292712A1/en
Assigned to PR PHARMACEUTICALS INC. reassignment PR PHARMACEUTICALS INC. RELEASE Assignors: SILICON VALLEY BANK
Assigned to PR PHARMACEUTICALS, INC. reassignment PR PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BROOKWOOD PHARMACEUTICALS, INC.
Assigned to BROOKWOOD PHARMACEUTICALS, INC. reassignment BROOKWOOD PHARMACEUTICALS, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR AND Assignors: PR PHARMACEUTICALS, INC.
Assigned to BROOKWOOD PHARMACEUTICALS, INC. reassignment BROOKWOOD PHARMACEUTICALS, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NUMBER Assignors: PR PHARMACEUTICALS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulations for controlled, prolonged release of bioactive molecules such as therapeutic proteins, peptides and oligonucleotides have been developed. These formulations are based on solid microparticles or nanoparticles formed of the combination of biodegradable, synthetic polymers such as poly (lactic acid) (PLA), poly (glycolic acid) (PGA), and copolymers thereof. Bioactive molecules are coupled to hydrophilic polymers such as polyethylene glycol or polypropylene glycol and formulated to provide controlled release. The bioactive molecules are more stable, less immunogenic and have improved release rate profiles with lower burst levels and increased drug loading relative to the same bioactive molecules lacking coupled hydrophilic polymers. The controlled release formulations can be administered by injection, by inhalation, nasally, or orally.

Description

    RELATED APPLICATIONS
  • This application is a Continuation application of U.S. Ser. No. 09/999,820 filed on Oct. 31, 2001 and claims priority to U.S. Provisional Application No. 60/244,499 entitled “Methods and Compositions for Enhanced Delivery of Bioactive Molecules” filed on Oct. 31, 2000, the contents of which are incorporated herein by reference.[0001]
    • BACKGROUND OF THE INVENTION
  • Encapsulation of pharmaceuticals in biodegradable polymer microspheres and nanospheres can prolong the maintenance of therapeutic drug levels relative to administration of the drug itself. Sustained release may be extended up to several months depending on the formulation and the active molecule encapsulated. However many bioactive molecules, and especially proteins, are damaged or made unstable by the procedures required to encapsulate them in the polymeric carriers. Furthermore, the charged, polar nature of many proteins may limit the extent of encapsulation in polymer drug carriers and may lead to rapid loss of a fraction of the encapsulated bioactive molecule when first administered (“burst”). [0002]
  • Encapsulation of bioactive molecules in biodegradable polymer delivery systems has been used to stimulate an immune response when administered to a patient (see U.S. Pat. No. 5,942,253 to Gombotz et al.). While this is a desired result in certain cases, it is undesirable when the purpose is delivery of the bioactive molecule for therapeutic purposes. Thus, diminished recognition by the immune system of bioactive molecules delivered using biodegradable polymers would be beneficial in a therapeutic setting. [0003]
  • Bioactive molecules, especially therapeutic proteins (drugs), may be modified with hydrophilic polymers (a process generally known as “pegylation”), such as polyethylene glycol, covalently attached to one or more amino acid side chains (see e.g., U.S. Pat. No. 4,179,337 to Davis et al.; U.S. Pat. No. 5,446,090 to Harris; U.S. Pat. No. 5,880,255 to Delgado et al.). While it is known in the art that such attachment may lead to an apparent increase in molecular mass and decreased blood clearance rate for the modified therapeutic protein (see e.g., U.S. Pat. No. 5,320,840 to Camble et al.), the prior art does not teach that diminished immunogenicity can be achieved or that the duration of release from biodegradable polymer drug delivery systems can be extended using pegylated proteins. The prior art does not teach that pegylation can increase the drug loading achievable in a biodegradable drug delivery system relative to the unpegylated drug, nor does it teach that reduced burst of drug is achievable for the pegylated moiety relative to the unpegylated drug. [0004]
    • SUMMARY OF THE INVENTION
  • The present invention provides novel formulations for controlled, prolonged release of bioactive molecules such as therapeutic proteins, peptides and oligonucleotides. The formulations are based on microparticles or nanoparticles formed of the combination of biodegradable, polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof. Bioactive molecules are coupled to hydrophilic polymers such as polyethylene glycol or polypropylene glycol and then formulated with the solid microparticles or nanoparticles to provide controlled release. The controlled release formulations can be administered by injection, by inhalation, nasally, or orally. [0005]
  • Accordingly, as part of the present invention, it has been discovered that attachment of hydrophilic polymers to bioactive molecules, such as drugs and therapeutic proteins, has several beneficial effects, including providing protection from degradation and denaturation under the conditions of encapsulation in drug carriers. Additionally the amount of modified protein that can be encapsulated is increased relative to the unmodified protein, thus providing a lower total dose of material, benefiting both the patient and producer. [0006]
  • In addition, the present invention is further based on the discovery that immunogenicity of peglyated bioactive molecules encapsulated in biodegradable polymer drug delivery carriers is decreased relative to non-peglyated bioactive molecules in the carriers, particularly when administered by subcutaneous or intramuscular injection or inhalation or mucosal delivery (e.g., oral or nasal delivery). Such diminished immunogenicity is particularly advantageous when biodegradable polymers are used for oral delivery, since this is a typical method for mucosal vaccination. [0007]
  • In another aspect, the present invention is based on the discovery that pegylated proteins, peptides, oligosaccharides and oligonucleotides, which normally are not absorbed from the gastro-intestinal tract, are made bioavailable by administration in biodegradable polymer systems, particularly nanospheres. The term “bioavailable”, as used herein, refers to the fraction of bioactive molecule that enters the blood stream following administration to a subject. The controlled release formulations of the invention increase the bioavailability of bioactive molecules and, in particular, the nanosphere formulations described herein when administered orally. For example, blood levels can be maintained for up to several days following a single oral administration of nanosphere encapsulated peglyated bioactive molecule. Additionally the polyethylene glycol chains protect the bioactive molecules from degradation and denaturation in the process of forming the nanospheres, contribute to increased entrapment of active material, and diminish the “burst” effect. [0008]
  • Thus, in a preferred embodiment, the invention provides a pharmaceutical composition for controlled, sustained release and increased bioavailability of a bioactive molecule, which includes a polymer (e.g., PEG) conjugated therapeutic agent encapsulated into nanospheres. In a particularly preferred embodiment, the composition is administered orally. [0009]
  • In a preferred embodiment, the bioactive molecule is selected from the group consisting of α-interferon, β-interferon, γ-interferon, erythropoietins, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, interleukin 1, interleukin 2, interleukin 3, interleukin 12, asparaginase, adenosine deaminase, insulin, ACTH, glucagon, somatostatin, somatotropin, thymosin, parathyroid hormone, pigmentary hormones, somatomedin, leuteinizing hormone, chorionic gonadotropin, hypothalmic releasing factors, antidiuretic hormones, thyroid stimulating hormone, endorphins, enkephalins, biphalin, prolactin, monoclonal antibodies, polyclonal antibodies, antisense oligonucleotides, aptamers, therapeutic genes, heparin, low molecular weight heparin and small bioactive molecules. [0010]
  • Accordingly, the compositions of the present invention can be used to improve in vivo delivery of therapeutic bioactive molecules in several respects. In particular, the invention provides the advantages of reduced immunogenicity, increased bioavailability, increased duration, increased stability, decreased burst and controlled, sustained release of bioactive molecules in vivo. [0011]
    • DETAILED DESCRIPTION OF THE INVENTION
  • I. Bioactive Molecules [0012]
  • The term “bioactive molecule”, as used herein, refers to any therapeutic protein, peptide, polysaccharide, nucleic acid or other biologically active compound for administration to a subject, such as a human or other mammal. Suitable therapeutic proteins for use in the invention include, but are not limited to, interferon-alphas, interferon-betas, interferon-gamma, erythropoetins, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor (GM-CSF), interleukin 1, interleukin 2, interleukin 3, interleukin 12, asparaginase, adenosine deaminase and insulin. [0013]
  • Suitable therapeutic peptides also include hormones, such as ACTH, glucagon, somatostatin, somatotropin, thymosin, parathyroid hormone, pigmentary hormones, somatomedin, luteinizing hormone, chorionic gonadotropin, hypothalmic releasing factors, antidiuretic hormones, thyroid stimulating hormone, endorphins, enkephalins, biphalin and prolactin. [0014]
  • Additional suitable therapeutic proteins include monoclonal and polyclonal antibodies, single-chain antibodies, other antibody fragments, analogs and derivatives. Therapeutic polynucleotides, including antisense oligonucleotides, aptamers and therapeutic genes also can be delivered using the methods and compositions of the invention. [0015]
  • Anticoagulant therapeutics, such as heparin and low molecular weight heparin, also can be delivered using the methods and compositions of the invention. Other suitable therapeutic proteins for the use in the invention include small bioactive molecules, such as anticancer drugs, e.g., paclitaxel, taxotere, doxorubicin and daunorubicin, vincristine, cisplatin, carboplatin, camptothecin and camptothecin analogs, antibiotics, antipsychotics, antidepressants, small molecule drugs for diabetes and cardiovascular disease. [0016]
  • II. Conjugation of Bioactive Molecules to Hydrophilic Polymers [0017]
  • The term “hydrophilic polymer” refers to any water-soluble linear or branched polymer including, but not limited to, polyethylene glycol and polypropylene glycol and similar linear and branched polymers. Preferably, the molecular weight of the polymer ranges from about 500 daltons to about 50,000 daltons. Hydrophilic polymers for use in the invention typically have a reactive group incorporated for attachment to the bioactive molecule of interest through amino, carboxyl, sulfhydryl, phosphate or hydroxyl functions. [0018]
  • Hydrophilic polymers used in the present invention, such as polyethylene glycol, can be prepared according to standard protocols with one end capped as with a methoxy group and the other end activated for facile conjugation to active groups on bioactive molecules. For example, U.S. Pat. No. 6,113,906 describes the use of succinamidyl succinate or carbamate reactive groups on the polyethylene glycol to react with amine groups on proteins. U.S. Pat. No. 5,446,090 describes the use of sulfone derivatives of polyethylene glycol to form stable bonds with sulfhydryl groups of proteins. U.S. Pat. No. 5,880,255 describes the use of tresyl derivatives for reaction at amine groups of proteins to form a simple, stable secondary amine linkage. The entire contents of these patents is incorporated by reference herein. N-hydroxy succinamide also may be incorporated as the reactive group. [0019]
  • III. Controlled Release Formulations for Polymer Conjugated Bioactive Molecules [0020]
  • The term “controlled release” refers to control of the rate and/or quantity of bioactive molecules delivered according to the drug delivery formulations of the invention. The controlled release can be continuous or discontinuous, and/or linear or non-linear. This can be accomplished using one or more types of polymer compositions, drug loadings, inclusion of excipients or degradation enhancers, or other modifiers, administered alone, in combination or sequentially to produce the desired effect. [0021]
  • Zero order or linear release is generally construed to mean that the amount of the bioactive molecule released over time remains relatively constant as a function of amount/unit time during the desired time frame. Multi-phasic is generally construed to mean that release occurs in more than one “burst”. [0022]
  • A. Microparticles [0023]
  • In one embodiment, the invention employs biodegradable microparticles for controlled release of polymer conjugated bioactive molecules. As used herein, “microparticles” refers to particles having a diameter of preferably less than 1.0 mm, and more preferably between 1.0 and 100.0 microns. Microparticles include microspheres, which are typically solid spherical microparticles. Microparticles also include microcapsules, which are spherical microparticles typically having a core of a different polymer, drug, or composition. [0024]
  • Microparticles for use in the present invention can be made using a variety of biodegradable polymers used for controlled release formulations, as are well known in the art. Suitable polymers for example include, but are not limited to, poly(hydroxy acids) including polylactic acid, polyglycolic acid, and copolymers thereof, polyanhydrides, polyorthoesters, and certain types of protein and polysaccharide polymers. The term “bioerodible” or “biodegradable”, as used herein, refer to polymers that dissolve or degrade within a period that is acceptable in the desired application (usually in vivo therapy), typically less than about five years, and more preferably less than about one year, once exposed to a physiological solution of pH between about 6-8 and at a temperature of between about 25° C.-38° C. [0025]
  • Preferred polymers include poly(hydroxy acids), especially poly(lactic acid-co-glycolic acid) (“PLGA”) that degrade by hydrolysis following exposure to the aqueous environment of the body. The polymer is then hydrolyzed to yield lactic and glycolic acid monomers, which are normal byproducts of cellular metabolism. The rate of polymer disintegration can vary from several weeks to periods of greater than one year, depending on several factors including polymer molecular weight, ratio of lactide to glycolide monomers in the polymer chain, and stereoregularity of the monomer subunits (mixtures of L and D stereoisomers disrupt the polymer crystallinity enhancing polymer breakdown). Microspheres may contain blends of two and more biodegradable polymers, of different molecular weight and/or monomer ratio. [0026]
  • Derivatized biodegradable polymers are also suitable for use in the present invention, including hydrophilic polymers attached to PLGA and the like. To form microspheres, in particular, a variety of techniques known in the art can be used. These include, for example, single or double emulsion steps followed by solvent removal. Solvent removal may be accomplished by extraction, evaporation or spray drying among other methods. [0027]
  • In the solvent extraction method, the polymer is dissolved in an organic solvent that is at least partially soluble in the extraction solvent such as water. The bioactive molecule, either in soluble form or dispersed as fine particles, is then added to the polymer solution, and the mixture is dispersed into an aqueous phase that contains a surface-active agent such as poly(vinyl alcohol). The resulting emulsion is added to a larger volume of water where the organic solvent is removed from the polymer/bioactive agent to form hardened microparticles. [0028]
  • In the solvent evaporation method, the polymer is dissolved in a volatile organic solvent. The bioactive molecule, either in soluble form or dispersed as fine particles, is then added to the polymer solution, and the mixture is suspended in an aqueous phase that contains a surface-active agent such as poly(vinyl alcohol). The resulting emulsion is stirred until most of the organic solvent evaporates, leaving solid microspheres. [0029]
  • In the spray drying method, the polymer is dissolved in a suitable solvent, such as methylene chloride (e.g., 0.04 g/ml). A known amount of bioactive molecule (drug) is then suspended (if insoluble) or co-dissolved (if soluble) in the polymer solution. The solution or the dispersion is then spray-dried. Microspheres ranging in diameter between one and ten microns can be obtained with a morphology, which depends on the selection of polymer. [0030]
  • Other known methods, such as phase separation and coacervation, and variations of the above, are known in the art and also may be employed in the present invention. [0031]
  • B. Nanoparticles [0032]
  • In another embodiment, the invention employs biodegradable nanoparticles for controlled release of polymer conjugated bioactive molecules, particularly for oral administration. As used herein, the term “nanoparticles” refers to particles having a diameter of preferably between about 20.0 nanometers and about 2.0 microns, typically between about 100 nanometers and 1.0 micron. [0033]
  • Formulation of nanoparticles can be achieved essentially as described above for microparticles, except that high speed mixing or homogenization is used to reduce the size of the polymer/bioactive agent emulsions to below about 2.0 microns, preferably below about 1.0 micron. For example, suitable techniques for making nanoparticles are described in WO 97/04747, the complete disclosure of which is incorporated by reference herein. [0034]
    • EXAMPLES
  • I. Preparation and Characterization of Formulations for Delivering Leu-Enkephalin [0035]
    • Example 1 Preparation of Polyethylene Glycol-Conjugated Leu-Enkephalin (PEG-Leu-Enkephalin)
  • Leu-enkephalin covalently modified with polyethylene glycol was prepared as follows: 25 mg of leu-enkephalin was dissolved in 500 μL of anhydrous DMSO containing 50 μL TEA. 250 mg of mPEG(5000)-SPA was dissolved in 1.5 mL anhydrous DMSO and added by direct injection to the peptide solution. The reaction was allowed to proceed for 2 hours at room temperature or until >90% of the peptide was converted to its PEG-modified form. Isolation of the product, mPEG(5000)-leu-enkephalin, from reactants was accomplished by recrystallization (2×) from EtOH. The reaction product was a white solid that was >95% pegylated (as assessed by RP-HPLC). [0036]
    • Example 2 Preparation and Characterization of Conventional (w1/o/w2) Microparticles Containing Leu-Enkephalin
  • Conventional w[0037] 1/o/w2 microparticles containing leu-enkephalin were prepared as follows: Leu-enkephalin was dissolved in a 1:9 DMSO:PBS mixture to a final concentration of 35 mg/mL (its maximum solubility in PBS). PLGA (50:50 lactide:glycolide; acid end group; inherent viscosity 0.16 L/g) was dissolved in methylene chloride to a final concentration of 200 mg/mL. The primary (w/o) emulsion was created by homogenizing 200 μL of the peptide solution with 3 mL of the polymer solution at 10,000 rpm for 3 minutes. This primary emulsion was poured into 100 mL of 0.5% PVA solution and stirred at a 750 rpm for 3-6 hours. After the solvent had evaporated and the microparticles had hardened, they were collected by filtration and dried in vacuo before analysis. The particles were characterized for core loading (CL), encapsulation efficiency (EE), particle size (PS), and initial release (IR) of their contents as follows. Table 1 shows the results.
  • Core loading measurement of the microspheres was done by dissolving 10 mg of microspheres in 50% acetonitrile followed by centrifugation to pellet the insoluble polymer. Aliquots were analyzed by RP-HPLC and compared to representative standards prepared in 50% acetonitrile. Initial release of contents from microspheres was measured by suspending 20 mg samples in 2 mL of PBS (50 mM, pH 7.2) containing 0.02% Tween 20 and 25% EtOH. The suspensions were vortexed and incubated at 37° C. After 1 hour, aliquots were removed, filtered and analyzed for the amount released by RP-HPLC. This accelerated release at 1 hour was shown to correlate well with the amount of active released after 1 day in PBS without EtOH. [0038]
    • Example 3 Preparation and Characterization of Conventional (w1/o/w2) Microparticles Containing PEG-Leu-Enkephalin Conjugate
  • Conventional w[0039] 1/o/w2 microparticles containing PEG-leu-enkephalin were prepared as follows: PEG-leu-enkephalin was dissolved in a 1:9 DMSO:PBS mixture to a final concentration of 50 mg/mL. PLGA (50:50 lactide:glycolide; acid end group; inherent viscosity 0.16 L/g) was dissolved in methylene chloride to a final concentration of 200 mg/mL. The primary (w/o) emulsion was created by homogenizing 200 μL of the peptide solution with 3 mL of the polymer solution at 10,000 rpm for 3 minutes. This primary emulsion was poured into 100 mL of 0.5% PVA solution and allowed to stir at a 750 rpm for 3-6 hours. After the solvent had evaporated and the microparticles had hardened, they were collected by filtration and dried in vacuo before analysis. The particles were characterized for core loading (CL), encapsulation efficiency (EE), particle size (PS), and initial release (IR) of their contents as described in Example 2. These data are presented in Table 1.
    • Example 4 Preparation and Characterization of Monophase Microparticles Containing Leu-Enkephalin
  • Monophase microparticles containing unmodified leu-enkephalin were prepared as follows: 10 mg of leu-enkephalin was dissolved in 1 mL methylene chloride containing 30 μL TFA. 90 mg of PLGA (50:50 lactide:glycolide; lauryl end group; inherent viscosity 0.61 L/g) was then dissolved in the organic peptide solution. The primary (o/w) emulsion was formed by vortexing this solution with 2.5 mL of 2.5% PVA for 3 minutes. Forced air (15 minutes) and stirring (6-8 hours) were used to evaporate the solvent and harden the microparticles. After hardening, the microparticles were collected by filtration and dried in vacuo before analysis. Data for core loading (CL), encapsulation efficiency (EE), particle size (PS), and initial release (IR) of contents are presented in Table 1. [0040]
    • Example 5 Preparation and Characterization of Monophase Microparticles Containing PEG-Leu-Enkephalin Conjugate
  • Monophase microparticles containing PEG-leu-enkephalin were prepared as follows: 50 mg PEG-leu-enkephalin and 150 mg PLGA (50:50 lactide:glycolide; lauryl end group; inherent viscosity 0.61 L/g) were dissolved in 2 mL methylene chloride. The primary (o/w) emulsion was formed by vortexing the organic peptide/polymer solution with 5 mL of 2.5% PVA for 3 minutes. The organic solvent was removed from the microparticles by stirring/vacuum evaporation for 2 hours. After microparticles hardened, they were collected by filtration and dried in vacuo before analysis. Data for core loading (CL), encapsulation efficiency (EE), particle size (PS), and initial release (IR) of contents are presented in Table 1. [0041]
    • Example 6 Increased Drug Loading for Pegylated Leu-Enkephalin
  • Data from Table 1 shows that covalent coupling of PEG 5000 to leu-enkephalin increases the drug loading (CL) attainable from 0.07% to 0.36% for the double emulsion technique and from 0.3% to 3.95% for the monophase method. Pegylation also resulted in greatly improved encapsulation efficiency for the two methods. The initial release (“burst”) was slightly less (better) for the pegylated than for unpegylated peptides made by the monophase, and the drug core load was more than 10 times greater for the pegylated peptide. The higher drug coreload allows smaller doses of biodegradable drug delivery systems to be administered to patients to achieve the desired drug dose. [0042]
    TABLE 1
    Characteristics of Leu-Enkephalin and
    PEG-Leu-Enkephalin Microparticles.
    Leu-enkephalin PEG-Leu-enkephalin
    Double- Double-
    emulsion Monophase emulsion Monophase
    TL (%)a 1.64 10 1.64 10
    CL (%) 0.07 0.3 0.36 3.95
    EE (%) 4.43 3.04 17 40.3
    PS (μm) 50-250 20-100 50-200 40-100
    IR (%) 47.1 22.5 ND 20.8
  • II. Preparation, Characterization and Administration of Formulations for Delivering Biphalin [0043]
    • Example 7 Increased Drug Loading and Decreased Burst for Pegylated Biphalin
  • Biphalin is a synthetic peptide with analgesic activity in mammals. With two PEG 2000 chains attached it has a longer duration of analgesic action after intravenous administration than does the unpegylated peptide. Biphalin and pegylated biphalin were compared for their behavior in PLGA microsphere encapsulation as described in the Examples below. As shown in Table 2, pegylated biphalin has a higher drug core loading, higher encapsulation efficiency, and lower initial release level (burst) than the unpegylated peptide. [0044]
    • Example 8 Preparation and Characterization of Conventional (w1/o/w2) Microparticles Containing Biphalin
  • Conventional w[0045] 1/o/w2 microparticles containing PEG-biphalin were prepared as follows: Biphalin was dissolved in a ternary PBS:DMSO:acetic acid (5:1:1.5) mixture to a final concentration of 35 mg/mL. PLGA (50:50 lactide:glycolide; acid end group; inherent viscosity 0.16 L/g) was dissolved in methylene chloride to a final concentration of 200 mg/mL. The primary (w/o) emulsion was created by homogenizing 200 μL of the peptide solution with 3 mL of the polymer solution at 10,000 rpm for 3 minutes. This primary emulsion was poured into 100 mL of 0.5% PVA solution and allowed to stir at 750 rpm for 3 hours. After the solvent had evaporated and the microparticles had hardened, they were washed with water, collected by filtration and dried in vacuo before analysis. Data for core loading (CL), encapsulation efficiency (EE), particle size (PS), and initial release (IR) of contents are shown in Table 2.
    • Example 9 Preparation and Characterization of Conventional (w1/o/w2) Microparticles Containing PEG-Biphalin Conjugate
  • Conventional w[0046] 1/o/w2 microparticles containing PEG-biphalin were prepared as follows: PEG-biphalin was dissolved in PBS to a final concentration of 50 mg/mL. PLGA (50:50 lactide:glycolide; acid end group; inherent viscosity 0.16 L/g) was dissolved in methylene chloride to a final concentration of 200 mg/mL. The primary (w/o) emulsion was created by homogenizing 200 μL of the peptide solution with 3 mL of the polymer solution at 10,000 rpm for 3 minutes. This primary emulsion was poured into 100 mL of 0.5% PVA solution and allowed to stir at a 750 rpm for 3 hours. After the solvent had evaporated and the microparticles had hardened, they were washed with water, collected by filtration and dried in vacuo before analysis. Data for core loading (CL), encapsulation efficiency (EE), particle size (PS), and initial release (IR) of contents are presented in Table 2.
    • Example 10 Preparation and Characterization of Monophase Microparticles Containing Biphalin
  • Monophase microparticles containing unmodified biphalin were prepared as follows: 20 mg of biphalin and 180 mg of PLGA (50:50 lactide:glycolide; lauryl end group; inherent viscosity 0.61 L/g) were dissolved in 2 mL of a 1:3 acetic acid:methylene chloride mixture. The primary emulsion was created by vortexing the oil phase with 5 mL of 1% PVA for 3 minutes. Removal of the organic solvents from the primary o/w emulsion was accomplished by vacuum evaporation under stirring for 4 hours. After solvent removal, the hardened microparticles were collected by filtration and washed several times with distilled-deionized water to remove any nonspecifically bound PVA or biphalin. Finally, the microparticles were dried in vacuo before analysis. Data for core loading (CL), encapsulation efficiency (EE), particle size (PS), and initial release (IR) of contents are shown in Table 2. [0047]
    • Example 11 Preparation and Characterization of Monophase Microparticles Containing PEG-Biphalin Conjugate
  • Monophase microparticles containing PEG-biphalin were prepared as follows: 180 mg of PLGA (50:50 lactide:glycolide; lauryl end group; inherent viscosity 0.61 L/g) and 20 mg of PEG-biphalin were dissolved in 2 mL methylene chloride. The primary emulsion was created by vortexing the polymer/peptide solution with 5 mL of 2.5% polyvinyl alcohol (PVA, 80-85% hydrolyzed) for 3 minutes. The organic solvent was removed from the primary emulsion (o/w) by vacuum evaporation under stirring for 4 hours. The hardened microparticles were collected by filtration and washed several times with distilled water to remove any nonspecifically bound PVA or PEG-biphalin. Finally, the microparticles were dried in vacuo before analysis. Data for core loading (CL), encapsulation efficiency (EE), particle size (PS), and initial release (IR) of contents are presented in Table 2. [0048]
    • Example 12 Analgesic Effect on a Mammal Following Administration of Pegylated Biphalin in a Biodegradable Microsphere
  • To evaluate the improved delivery in vivo of biphalin administered according to the present invention, a comparison study can be performed as follows: Pegylated biphalin PLGA microspheres can be prepared by the double emulsion method as described in Example 9. The microspheres are suspended in a medium of carboxymethylacellulose (0.5%) in water with 0.5% Tween-20. An effective dose is then administered subcutaneously to Sprague-Dawley rats and the analgesic effect is measured by, for example, the tail-flick assay. The microsphere-encapsulated PEG-biphalin has an analgesic effect which last longer than that for an unencapsulated PEG-biphalin control injection. The experiment can be repeated with PLGA-encapsulated PEG-biphalin prepared by the monophase method of Example 11 with similar results. [0049]
    TABLE 2
    Characteristics of Biphalin and PEG-Biphalin Microparticles
    Biphalin PEG-Biphalin
    Double- Double-
    emulsion Monophase emulsion Monophase
    TL (%)a 1.0 10 1.64 10
    CL (%) 0.24 0.36 1.48 6.86
    EE (%) 14.28 3.64 90.52 68.6
    PS (μm) 50-250 20-100 20-200 20-100
    IR (%) ND 49.4 19 15.6
  • III. Preparation, Characterization and Administration of Formulations for Delivering Insulin [0050]
    • Example 13 Preparation of Polyethylene Glycol-Conjugated Human Insulin (PEG-Insulin)
  • Human insulin was covalently modified with polyethylene glycol as follows: 116 mg of recombinant human insulin was dissolved in 4 mL anhydrous DMSO containing 200 μL TEA. 1 g of mPEG(5000)-SPA was dissolved in 10 mL anhydrous DMSO and added to the insulin solution by direct injection. The reaction proceeded overnight (6-10 hours) at room temperature or until >90% of the protein was pegylated. The unreacted PEG and pegylated insulin were isolated by precipitation (2×) from Et[0051] 2O. The final product was a white granular solid that was >95% pegylated (according to RP-HPLC analysis).
    • Example 14 Preparation and Characterization of Conventional (w1/o/w2) Microparticles Containing Human Insulin
  • Conventional w[0052] 1/o/w2 microparticles containing human insulin were prepared as follows: recombinant human insulin was dissolved in DMSO:0.1N HCl (1:1) to a final concentration of 50 mg/mL and PLGA (50:50 lactide:glycolide; lauryl end group; inherent viscosity 0.61 L/g) was dissolved in methylene chloride to a final concentration of 200 mg/mL. The primary (w/o) emulsion was formed by homogenization of 200 μL of the protein solution and 3 mL of the polymer solution at 10,000 rpm for 3 minutes. This primary emulsion was then added to 100 mL of 0.5% PVA and allowed to stir under vacuum for 3-6 hours. Once the organic solvents were removed, the microparticles were filtered, washed several times with water, and dried in vacuo before analysis. Table 3 lists characteristics of the microparticles.
    • Example 15 Preparation and Characterization of Conventional (w1/o/w2) Microparticles Containing PEG-Insulin Conjugate
  • Conventional w[0053] 1/o/w2 microparticles containing PEG-insulin were prepared as follows: PEG-insulin was dissolved in a DMSO:H2O (1:2) mixture to a final concentration of 50 mg/mL and PLGA (50:50 lactide:glycolide; lauryl end group; inherent viscosity 0.61 L/g) was dissolved in methylene chloride to a final concentration of 200 mg/mL. The primary (w/o) emulsion was formed by homogenization of 200 μL of the protein solution and 3 mL of the polymer solution at 10,000 rpm for 3 minutes. This primary emulsion was the added to 100 mL of 0.5% PVA and allowed to stir under vacuum for 3-6 hours. Once the organic solvents were removed, the microparticles were filtered, washed several times with water, and dried in vacuo before analysis. Table 3 lists results from analysis of the microparticles.
    • Example 16 Preparation and Characterization of Monophase Microparticles Containing Human Insulin
  • Monophase microparticles containing human insulin were prepared as follows: 20 mg of recombinant human insulin (Zn[0054] 2+-insulin salt) was dissolved in 2 mL of an acetic acid:methylene chloride (1.4:1) mixture. 180 mg of PLGA (50:50 lactide:glycolide; lauryl end group; inherent viscosity 0.61 L/g) was then dissolved in the organic peptide solution. The primary emulsion was created by vortexing the organic peptide/polymer solution with 5 mL of 1% PVA for 3 minutes. The organic solvents were removed by vacuum evaporation under stirring for 2 hours. The partially hardened microparticles were added to a beaker containing 100 mL water and stirred for another 2 hours to completely remove all organic solvents. The microparticles were collected by filtration, washed several times with water and dried in vacuo before analysis. Table 3 lists results from analysis of the microparticles.
    • Example 17 Preparation and Characterization of Monophase Microparticles Containing PEG-Insulin Conjugate
  • Monophase microparticles containing PEG-insulin were prepared as follows: 63 mg of PEG-insulin and 137 mg of PLGA (50:50 lactide:glycolide; lauryl end group; inherent viscosity 0.61 L/g) were dissolved in 2 mL of methylene chloride. The primary emulsion was formed by vortexing the oil phase with 5 mL of 1% PVA for 3 minutes. Solvent removal was accomplished by vacuum evaporation for 2 h followed by stirring under ambient conditions for 1 hour. The hardened microparticles were collected by filtration and washed several times with water before drying in vacuo and analyzing. Table 3 lists results from analysis of the microparticles. [0055]
    • Example 18 Increased Drug Loading and Encapsulation Efficiency for Pegylated Insulin
  • Data in Table 3 show that pegylated insulin achieves increased drug loading in PLGA microspheres prepared by both the monophase and double emulsion methods. Pegylated insulin also has higher encapsulation efficiency, a major advantage when high value biologically active peptides and proteins are used. [0056]
    TABLE 3
    Characteristics of Insulin and PEG-Insulin Microparticles.
    Insulin PEG-Insulin
    Double- Double-
    emulsion Monophase emulsion Monophase
    TL (%)a 1.64 10 1.64 31.5
    CL (%) 0.23 0.6 0.54 15.5
    EE (%) 13.86 6 33 49.2
    PS (μm) 100-350 30-100 50-250 50-100
    • Example 19 Hypoglycemic Effect of PLGA-Encapsulated PEG-Insulin
  • PEG-Insulin PLGA microspheres and an equivalent dose of free insulin were administered subcutaneously to normal rats. Blood was drawn periodically and anticoagulated. Blood glucose levels were measured by standard tests. As shown in Table 4, use of PEG-insulin in PLGA microspheres significantly suppressed the initial reduction in blood glucose relative to the values observed for unmodified insulin. In addition, these data importantly show that the PEG-insulin microsphere preparation released its drug in a biologically active form that was able to effectively depress blood glucose levels in an in vivo animal model without the “burst” effect of unmodified, conventional formulations. [0057]
    TABLE 4
    In Vivo Study of Insulin and PEG-Insulin Microparticles.
    Insulin (Humulin-U) PEG-Insulin
    Time (hr) % BGLa SD % BGLa SD
    0 100 0 100 0
    1 25.8 6.6 111.1 16
    2 14.9 11.4 86.5 17.6
    4 68.1 11.6 97 13.3
    6 89.3 7 98.5 12.1
    8 75 1.7 82 6.8
    12 75.8 8.2 88.8 6.6
  • IV. Preparation and Characterization of Formulations for Delivering GM-CSF [0058]
    • Example 20 Preparation of Polyethylene Glycol Conjugated GM-CSF
  • GM-CSF can be covalently conjugated to polyethylene glycol (PEG) as follows: 100 mg of GM-CSF is dissolved in 10 ml pH 7.5 phosphate buffer, at room temperature. 100 mg tresyl-monomethoxy-polyethylene glycol (MW=5000 daltons) is then added, and the mixture stirred for 1 hour. The unreacted GM-CSF and pegylated GM-CSF fractions are isolated from unreacted tresyl-monomethoxy-polyethylene glycol by gel chromatography. The pegylated GM-CSF is then dialyzed into 100 mM Tris buffer and adjusted to a concentration of 50 mg/ml. [0059]
    • Example 21 Preparation of Microparticles Encapsulating Pegylated GM-CSF
  • Microparticles encapsulating pegylated GM-CSF can be prepared as follows: 6.0 gm of PLGA (50:50 lactide:glycolide; inherent viscosity 0.35 l/g) is dissolved in 20 ml ethyl acetate. 1 ml of pegylated GM-CSF from Example 20 is added and stirred rapidly with a homogenizer at 10,000 rpm to create a water-in-oil emulsion. The polymer/drug/ethyl acetate emulsion is then pumped through a static mixer in combination with a pumped stream of water containing 1% polyvinyl alcohol (PVA). This action produces a w/o/w emulsion, which was subsequently added to 1 liter of 5C water with stirring. After 2 hours the hardened PLGA microspheres containing pegylated GM-CSF are collected on a 25 micron sieve and dried. The resulting microspheres will be in a size range of between 25-200 μm. [0060]
    • Example 22 Preparation of Nanoparticles Encapsulating Pegylated GM-CSF
  • Nanoparticles encapsulating pegylated GM-CSF can be prepared as follows: 3.0 gm of PLGA (material same as in Example 21) is dissolved in 5 ml dichloromethane and 5 ml acetone. 0.5 ml of pegylated GM-CSF from Example 20 is added and the mixture stirred at 10,000 rpm with a homogenizer. The mixture is added to 200 ml water containing 5% PVA. The mixture is then homogenized at 15,000 rpm for such time as is required to form nanoparticles of less than about 1.0 micron in diameter. The organic solvents can be removed by vacuum and the nanospheres can be recovered from the water and dried. [0061]
  • Equivalents [0062]
  • Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. In addition, the entire contents of all patents and publications cited herein is hereby incorporated by reference. [0063]

Claims (22)

What is claimed is:
1. A pharmaceutical formulation for controlled release of an interferon, the formulation comprising a biodegradable polymer in combination with a conjugate of an interferon and a hydrophilic polymer, wherein the conjugate of the hydrophilic polymer and an interferon is predominantly a single species.
2. The pharmaceutical formulation of claim 1, wherein the interferon is selected from the group consisting of alpha-interferon, beta-interferon, and gamma-interferon.
3. The pharmaceutical formulation of claim 1, wherein the interferon and the hydrophilic polymer are covalently conjugated.
4. The pharmaceutical formulation of claim 1, wherein the biodegradable polymer is selected from the group consisting of polyhydroxy acids, polylactic acids, polyglycolic acids, and copolymers thereof.
5. The pharmaceutical formulation of claim 4, wherein the biodegradable polymer is selected from the group consisting of polyanhydrides, polyorthoesters, and polysaccharide polymers.
6. The pharmaceutical formulation of claim 1, wherein the hydrophilic polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, copolymers of polyethylene glycol and polypropylene glycol, and linear and branched derivatives of polyethylene glycol and polyethylene glycol/polypropylene glycol copolymers.
7. The formulation of claim 1, wherein the formulation is in a form suitable for administration orally.
8. The formulation of claim 1, wherein the formulation is in a form suitable for administration by inhalation or mucosal delivery.
9. The formulation of claim 1, wherein the formulation is in a form suitable for administration by injection.
10. The formulation of claim 9, wherein the injection is subcutaneous or intramuscular.
11. The formulation of claim 1, wherein the biodegradable polymer comprises a copolymer of polylactic acid and polyglycolic acid and the hydrophilic polymer comprises polyethylene glycol.
12. A method for producing a pharmaceutical formulation for controlled release of an interferon, the method comprising:
dissolving (a) a biodegradable polymer and (b) a conjugate of an interferon and a hydrophilic polymer in a solvent to form a monophase, and
forming microparticles or nanoparticles comprising the biodegradable polymer encapsulating the conjugate.
13. The method of claim 12, wherein the interferon is selected from the group consisting of alpha-interferon, beta-interferon, and gamma-interferon.
14. A pharmaceutical formulation for controlled release of an interferon, the formulation comprising a biodegradable polymer in combination with a conjugate of an interferon and a hydrophilic polymer, wherein the biodegradable polymer comprises a derivatized biodegradable polymer containing hydrophilic and hydrophobic regions.
15. The formulation of claim 14, wherein the hydrophilic region comprises polyethylene glycol.
16. The formulation of claim 14, wherein the hydrophobic region comprises a polymer selected from the group consisting of polyhydroxy acids, polylactic acids, polyglycolic acids, and copolymers thereof.
17. The formulation of claim 15, wherein the polyethylene glycol is linked to the interferon predominantly at a single site on the bioactive molecule.
18. The pharmaceutical formulation of claim 14, wherein the interferon is selected from the group consisting of alpha-interferon, beta-interferon, and gamma-interferon.
19. A pharmaceutical formulation for controlled release of a bioactive molecule, the formulation comprising a biodegradable polymer in combination with a conjugate of a bioactive molecule and a hydrophilic polymer, wherein the formulation is in the form of microparticles encapsulating the conjugate, the microparticles having a diameter predominantly between 20 and 100 um.
20. The pharmaceutical formulation of claim 19, wherein the bioactive molecule is a protein.
21. A pharmaceutical formulation for controlled release of a peptide, the formulation comprising a biodegradable polymer in combination with a conjugate of a peptide and a hydrophilic polymer, wherein the conjugate is predominantly a single species.
22. The pharmaceutical formulation of claim 21, wherein the peptide comprises biphalin, leu-enkephalin, or somatostatin.
US10/766,106 2000-10-31 2004-01-27 Methods and compositions for enhanced delivery of bioactive molecules Abandoned US20040185103A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/766,106 US20040185103A1 (en) 2000-10-31 2004-01-27 Methods and compositions for enhanced delivery of bioactive molecules
US12/186,203 US20080292712A1 (en) 2000-10-31 2008-08-05 Methods and compositions for enhanced delivery of bioactive molecules

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24449900P 2000-10-31 2000-10-31
US09/999,820 US6706289B2 (en) 2000-10-31 2001-10-31 Methods and compositions for enhanced delivery of bioactive molecules
US10/766,106 US20040185103A1 (en) 2000-10-31 2004-01-27 Methods and compositions for enhanced delivery of bioactive molecules

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/999,820 Continuation US6706289B2 (en) 2000-10-31 2001-10-31 Methods and compositions for enhanced delivery of bioactive molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/186,203 Continuation US20080292712A1 (en) 2000-10-31 2008-08-05 Methods and compositions for enhanced delivery of bioactive molecules

Publications (1)

Publication Number Publication Date
US20040185103A1 true US20040185103A1 (en) 2004-09-23

Family

ID=22923012

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/999,820 Expired - Lifetime US6706289B2 (en) 2000-10-31 2001-10-31 Methods and compositions for enhanced delivery of bioactive molecules
US10/766,106 Abandoned US20040185103A1 (en) 2000-10-31 2004-01-27 Methods and compositions for enhanced delivery of bioactive molecules
US12/186,203 Abandoned US20080292712A1 (en) 2000-10-31 2008-08-05 Methods and compositions for enhanced delivery of bioactive molecules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/999,820 Expired - Lifetime US6706289B2 (en) 2000-10-31 2001-10-31 Methods and compositions for enhanced delivery of bioactive molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/186,203 Abandoned US20080292712A1 (en) 2000-10-31 2008-08-05 Methods and compositions for enhanced delivery of bioactive molecules

Country Status (8)

Country Link
US (3) US6706289B2 (en)
EP (2) EP1353701B1 (en)
JP (2) JP2004534721A (en)
CN (2) CN1507357A (en)
AT (1) ATE537845T1 (en)
AU (2) AU2002220002B2 (en)
ES (1) ES2382636T3 (en)
WO (1) WO2002036169A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058222A1 (en) * 2004-09-14 2006-03-16 Miller Landon C Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
US20060263328A1 (en) * 2005-05-19 2006-11-23 Sang Van Hydrophilic polymers with pendant functional groups and method thereof
US10702611B2 (en) 2014-12-02 2020-07-07 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
US10898576B2 (en) 2016-03-16 2021-01-26 Yanhui Xie Glucocorticoid combined with polyethylene glycol-modified interleukin 2 for treating respiratory disease

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098320B1 (en) 1996-07-29 2006-08-29 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6582921B2 (en) 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
CA2262018C (en) 1996-07-29 2007-10-02 Nanosphere Llc Nanoparticles having oligonucleotides attached thereto and uses therefor
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6984491B2 (en) 1996-07-29 2006-01-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6974669B2 (en) 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
AU774593C (en) 2000-01-13 2005-06-23 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
AU7687001A (en) 2000-07-11 2002-01-21 Nanospherre Inc Method of detection by enhancement of silver staining
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
DE60228128D1 (en) 2001-11-09 2008-09-18 Nanosphere Inc Bioconjugate NANOPARTICLE PROBES
KR100479735B1 (en) * 2002-05-25 2005-03-30 이현철 Non-oral vaccine for preventing dental caries using mannose-coated polymeric micelle-immunoregulator-immunogen complex
EP1570269B1 (en) * 2002-11-25 2011-06-08 Sciclone Pharmaceuticals, Inc. Methods of protecting against radiation damage using alpha thymosin
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
ES2427092T3 (en) * 2003-04-10 2013-10-28 Evonik Corporation A method for the production of emulsion-based microparticles
AU2004229461A1 (en) * 2003-04-11 2004-10-28 Pr Pharmaceuticals Inc. Method for preparation of site-specific protein conjugates
ES2315680T3 (en) 2003-06-26 2009-04-01 Psivida Inc. IN SITU GELIFICATION PHARMACY DISTRIBUTION SYSTEM.
ATE536861T1 (en) 2003-06-26 2011-12-15 Control Delivery Sys Inc BIOERODABLE SUSTAINED RELEASE DRUG DELIVERY SYSTEMS
CA2532302C (en) * 2003-07-15 2016-12-20 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
BRPI0412211A (en) * 2003-07-23 2006-08-22 Pr Pharmaceuticals Inc controlled release compositions
US7906148B2 (en) 2003-07-31 2011-03-15 Boston Scientific Scimed, Inc. Latex medical articles for release of antimicrobial agents
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
ATE420660T1 (en) 2003-08-08 2009-01-15 Amgen Fremont Inc ANTIBODIES TO PARATH HORMONE (PTH) AND THEIR USES
WO2005023293A1 (en) * 2003-09-09 2005-03-17 Pohang University Of Science And Technology Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
ES2246694B1 (en) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. PEGILATED NANOPARTICLES.
US20050260272A1 (en) * 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
US9561309B2 (en) * 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
ES2355642T3 (en) * 2004-07-16 2011-03-29 Nektar Therapeutics CONJUGATES UNDERSTANDING A PORTION OF GM-CSF AND A POLYMER.
CA2910494C (en) 2004-07-19 2018-10-23 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
EP1835885A1 (en) * 2004-12-23 2007-09-26 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of a gnrh
US7794742B2 (en) * 2005-02-08 2010-09-14 University Of Washington Devices for promoting epithelial cell differentiation and keratinization
US7824691B2 (en) * 2005-04-04 2010-11-02 Centegen, Inc. Use of RIP in treating staphylococcus aureus infections
CA2605551A1 (en) * 2005-05-10 2006-11-16 Naomi Balaban Compositions for administering rnaiii-inhibiting peptides
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
CN1939316B (en) * 2005-09-28 2012-01-25 中国人民解放军军事医学科学院毒物药物研究所 Microsphere containing adriamycin, its usage and preparation
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
CU23388B6 (en) * 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech PHARMACEUTICAL COMPOSITION OF MICROSPHERES TO PREVENT AMPUTATION OF THE DIABETIC FOOT
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7553940B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
JP2009538356A (en) * 2006-05-26 2009-11-05 アミリン・ファーマシューティカルズ，インコーポレイテッド Compositions and methods for the treatment of congestive heart failure
US20090053210A1 (en) * 2006-09-01 2009-02-26 Roland Buelow Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
US8481084B2 (en) 2007-05-23 2013-07-09 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
WO2009052301A1 (en) * 2007-10-16 2009-04-23 Regado Biosciences, Inc. Steady-state subcutaneous administration of aptamers
MX2010003979A (en) * 2007-10-16 2010-06-02 Biocon Ltd An orally administerable solid pharmaceutical composition and a process thereof.
CA2704921C (en) 2007-11-06 2015-11-24 Ellis L. Kline Compositions and methods for treating parkinson's disease and related disorders
ES2392375T3 (en) * 2007-12-13 2012-12-10 Kyushu University, National University Corporation Nanoparticles containing drugs that comprise pioglitazone
WO2009105692A1 (en) * 2008-02-21 2009-08-27 Rutgers, The State University Of New Jersey Compositions and methods for treating ophthalmic diseases
CN102958512B (en) 2008-08-29 2015-04-29 健赞股份有限公司 Controlled-released peptide formulations
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010033239A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of biphalin peptides
CN101822641B (en) * 2009-03-04 2012-04-11 上海交通大学医学院 K237 polypeptide-modified invisible nanoparticles and application thereof
CN101822642B (en) * 2009-03-04 2012-02-15 上海交通大学医学院 Peptide modified invisible nano particle loaded with anti-tumor angiogenesis drug and application thereof
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
IN2012DN00407A (en) 2009-08-05 2015-08-21 Pieris Ag
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
LT2637694T (en) 2010-11-12 2021-05-25 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
US10258941B2 (en) 2010-12-23 2019-04-16 Evonik Corporation Apparatus and methods for preparing an emulsion
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
CN102250251A (en) * 2011-06-29 2011-11-23 河北师范大学 Polyethylene glycol derivative of enkephalin analogue
WO2013013038A2 (en) * 2011-07-19 2013-01-24 Trustees Of Boston University Doping agents and polymeric compositions thereof for controlled drug delivery
KR20140102759A (en) * 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 Modified nucleoside, nucleotide, and nucleic acid compositions
KR101811917B1 (en) 2012-01-19 2017-12-22 더 존스 홉킨스 유니버시티 Nanoparticles formulations with enhanced mucus penetration
EA030318B1 (en) 2012-03-16 2018-07-31 Дзе Джонс Хопкинс Юниверсити Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
MY167814A (en) 2012-04-19 2018-09-26 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
JP6360039B2 (en) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド Composition comprising a plurality of coated particles, pharmaceutical composition, pharmaceutical formulation and method of forming the particles
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
CA2891393A1 (en) 2012-11-20 2014-05-30 Opko Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
SG10201705121PA (en) * 2012-12-21 2017-07-28 Advanced Medical Frontier Co Ltd Composition and food or drink
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (en) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Therapeutic compounds and their uses
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
AU2014340095A1 (en) 2013-10-22 2016-05-26 Prolynx Llc Conjugates of somatostatin and its analogs
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP6426194B2 (en) 2013-11-01 2018-11-21 カラ ファーマシューティカルズ インコーポレイテッド Crystalline forms of therapeutic compounds and uses thereof
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
KR20150140177A (en) * 2014-06-05 2015-12-15 한미약품 주식회사 Method of decreasing immunogenicity of protein and pepteide
EP3233056B1 (en) 2014-12-15 2023-11-15 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of ocular disorders
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN108289851B (en) 2015-06-19 2021-06-01 Opko生物科学有限公司 Long-acting coagulation factor and production method thereof
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
EA038755B1 (en) 2015-11-12 2021-10-14 Грейбаг Вижн, Инк. Aggregating microparticles for providing sustained release of a therapeuic agent for intraocular delivery
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562113A (en) 2016-05-10 2019-04-02 C4医药公司 Loop coil degron body for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
AU2017290593A1 (en) 2016-06-27 2019-01-03 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CN109789143A (en) 2016-07-01 2019-05-21 G1治疗公司 Antiproliferative based on pyrimidine
US11141434B2 (en) 2016-07-07 2021-10-12 Iovance Biotherapeutics, Inc. Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MA46669A (en) 2016-10-26 2019-09-04 Iovance Biotherapeutics Inc RE-STIMULATION OF LYMPHOCYTES INFILTRATION OF CRYOPRESERVED TUMORS
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
CN110199016A (en) 2016-11-17 2019-09-03 艾欧凡斯生物治疗公司 Tumors remaining lymphocyte infiltration and its preparation and application
US11357841B2 (en) 2017-01-06 2022-06-14 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
US20200121719A1 (en) 2017-01-06 2020-04-23 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
US11850285B2 (en) 2017-03-07 2023-12-26 North Carolina State University Insulin-responsive glucagon delivery patch
AU2018240462C1 (en) 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
JOP20190224A1 (en) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20200224161A1 (en) 2017-05-10 2020-07-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
CN111201040A (en) 2017-05-10 2020-05-26 灰色视觉公司 Sustained release microparticles and suspensions thereof for medical therapy
TW201919662A (en) 2017-06-05 2019-06-01 美商艾歐凡斯生物治療公司 Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
EP3710576A1 (en) 2017-11-17 2020-09-23 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
CA3083118A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
JP2021508104A (en) 2017-12-15 2021-02-25 アイオバンス バイオセラピューティクス，インコーポレイテッド Systems and methods for determining beneficial administration of tumor-infiltrating lymphocytes and their use, as well as beneficial administration of tumor-infiltrating lymphocytes and their use.
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
BR112020013848A2 (en) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. methods for expanding tumor-infiltrating lymphocytes and for treating an individual with cancer, tumor-infiltrating lymphocyte population, and, method for evaluating transcription factors
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
JP2021519337A (en) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Cereblon binder for the degradation of Ikaras
JP2021519336A (en) 2018-03-28 2021-08-10 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス IL-2 conjugate
MX2020010264A (en) 2018-03-29 2020-11-06 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy.
KR20210005138A (en) 2018-04-27 2021-01-13 이오반스 바이오테라퓨틱스, 인크. Closure method for expansion and gene editing of tumor infiltrating lymphocytes and their use in immunotherapy
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2021535112A (en) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド Pharmaceutical compounds for the treatment of medical disorders of complement D factor
TW202031273A (en) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 Treatment of nsclc patients refractory for anti-pd-1 antibody
SG11202101787XA (en) 2018-09-20 2021-04-29 Iovance Biotherapeutics Inc Expansion of tils from cryopreserved tumor samples
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
CN111122851A (en) * 2018-10-31 2020-05-08 博阳生物科技（上海）有限公司 Preparation method of anti-interference agent and application of anti-interference agent prepared by method
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
JP2022506586A (en) 2018-11-05 2022-01-17 アイオバンス バイオセラピューティクス，インコーポレイテッド Process for the production of tumor-infiltrating lymphocytes and their use in immunotherapy
KR20210091212A (en) 2018-11-05 2021-07-21 이오반스 바이오테라퓨틱스, 인크. Treatment of NSCLC Patients Refractory to Anti-PD-1 Antibodies
KR20210099573A (en) 2018-11-05 2021-08-12 이오반스 바이오테라퓨틱스, 인크. Selection of improved tumor-reactive T-cells
CA3123392A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
KR20210136050A (en) 2019-03-01 2021-11-16 이오반스 바이오테라퓨틱스, 인크. Expansion of tumor-infiltrating lymphocytes from liquid tumors and their therapeutic use
WO2020194034A1 (en) 2019-03-27 2020-10-01 Universidad De Chile Nanoparticle of chitosan and cyclodextrin containing encapsulated interferon and pharmaceutical compositions that contain it
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2023506734A (en) 2019-12-11 2023-02-20 アイオバンス バイオセラピューティクス，インコーポレイテッド Process for the production of tumor-infiltrating lymphocytes (TIL) and methods of using same
EP4077641A1 (en) 2019-12-20 2022-10-26 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
CN115997008A (en) 2020-04-22 2023-04-21 艾欧凡斯生物治疗公司 Systems and methods for coordinating the manufacture of cells for patient-specific immunotherapy
TW202208616A (en) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 Selection of improved tumor reactive t-cells
JP2023523855A (en) 2020-05-04 2023-06-07 アイオバンス バイオセラピューティクス，インコーポレイテッド Method for producing tumor-infiltrating lymphocytes and their use in immunotherapy
JP2023527919A (en) 2020-06-03 2023-06-30 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス IL-2 sequences and uses thereof
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022125941A1 (en) 2020-12-11 2022-06-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022133149A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
JP2023554395A (en) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment with tumor-infiltrating lymphocyte therapy in combination with CTLA-4 and PD-1 inhibitors
WO2022130015A2 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
EP4262828A1 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
CA3205464A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
JP2024501845A (en) 2020-12-31 2024-01-16 アイオバンス バイオセラピューティクス，インコーポレイテッド Devices and processes for automated production of tumor-infiltrating lymphocytes
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
EP4301138A2 (en) 2021-03-05 2024-01-10 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions
CA3212439A1 (en) 2021-03-19 2022-09-22 Michelle SIMPSON-ABELSON Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
CA3213080A1 (en) 2021-03-23 2022-09-29 Krit RITTHIPICHAI Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
KR20240032711A (en) 2021-03-25 2024-03-12 이오반스 바이오테라퓨틱스, 인크. Methods and compositions for use in T-cell co-culture efficacy assays and cell therapeutics
KR20240037185A (en) 2021-04-19 2024-03-21 이오반스 바이오테라퓨틱스, 인크. Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy
EP4340850A1 (en) 2021-05-17 2024-03-27 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3226111A1 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
AU2022343729A1 (en) 2021-09-09 2024-03-21 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
WO2023049862A1 (en) 2021-09-24 2023-03-30 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
AR127482A1 (en) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023220608A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024055017A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024055018A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5320840A (en) * 1990-07-23 1994-06-14 Imperial Chemical Industries Plc Continuous release pharmaceutical compositions
US5407609A (en) * 1989-05-04 1995-04-18 Southern Research Institute Microencapsulation process and products therefrom
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5880255A (en) * 1988-10-20 1999-03-09 Polymasc Pharmaceuticals Plc Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct of PEG and granulocyte-macrophage colony stimulating factor
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US5985265A (en) * 1994-10-12 1999-11-16 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6379704B2 (en) * 2000-05-19 2002-04-30 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
AU6876098A (en) * 1997-04-04 1998-10-30 Rhoda Inc Cerium oxides, zirconium oxides, ce/zr mixed oxides and ce/zr solid solutions having improved thermal stability and oxygen storage capacity
WO1998046212A1 (en) * 1997-04-17 1998-10-22 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US6165509A (en) * 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
CA2429254A1 (en) 2000-11-20 2002-05-30 James M. Dunn Oral nanosphere delivery

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5880255A (en) * 1988-10-20 1999-03-09 Polymasc Pharmaceuticals Plc Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct of PEG and granulocyte-macrophage colony stimulating factor
US5407609A (en) * 1989-05-04 1995-04-18 Southern Research Institute Microencapsulation process and products therefrom
US5320840A (en) * 1990-07-23 1994-06-14 Imperial Chemical Industries Plc Continuous release pharmaceutical compositions
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5985265A (en) * 1994-10-12 1999-11-16 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6403114B1 (en) * 1996-05-07 2002-06-11 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
US5916598A (en) * 1996-05-07 1999-06-29 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US6110503A (en) * 1996-05-07 2000-08-29 Alkermes Controlled Therapeutics Inc. Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6379703B1 (en) * 1998-12-30 2002-04-30 Alkermes Controlled Therapeutics Inc., Ii Preparation of microparticles having a selected release profile
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6596316B2 (en) * 1998-12-30 2003-07-22 Alkermes Controlled Therapeutics, Inc. Ii Preparation of microparticles having a selected release profile
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6440493B1 (en) * 1999-05-03 2002-08-27 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6379704B2 (en) * 2000-05-19 2002-04-30 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058222A1 (en) * 2004-09-14 2006-03-16 Miller Landon C Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
US8420602B2 (en) 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
US20060263328A1 (en) * 2005-05-19 2006-11-23 Sang Van Hydrophilic polymers with pendant functional groups and method thereof
US10702611B2 (en) 2014-12-02 2020-07-07 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
US10898576B2 (en) 2016-03-16 2021-01-26 Yanhui Xie Glucocorticoid combined with polyethylene glycol-modified interleukin 2 for treating respiratory disease

Also Published As

Publication number Publication date
EP1353701B1 (en) 2011-12-21
EP2316490A3 (en) 2012-02-01
US20080292712A1 (en) 2008-11-27
ES2382636T3 (en) 2012-06-12
AU2002220002B2 (en) 2006-12-14
US20020155158A1 (en) 2002-10-24
WO2002036169A3 (en) 2003-07-31
EP2316490A2 (en) 2011-05-04
CN101584867A (en) 2009-11-25
JP2010235584A (en) 2010-10-21
US6706289B2 (en) 2004-03-16
JP5737843B2 (en) 2015-06-17
CN1507357A (en) 2004-06-23
WO2002036169A2 (en) 2002-05-10
AU2000202A (en) 2002-05-15
JP2004534721A (en) 2004-11-18
EP1353701A2 (en) 2003-10-22
ATE537845T1 (en) 2012-01-15

Similar Documents

Publication Publication Date Title
US6706289B2 (en) Methods and compositions for enhanced delivery of bioactive molecules
AU2002220002A1 (en) Methods and compositions for enhanced delivery of bioactive molecules
US6482413B1 (en) Vitamin B12 —biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines
JP5165240B2 (en) Sustained release composition
JP5103022B2 (en) Calcium phosphate nanoparticle cores, particles containing biomolecules and bile acids, and methods for their production and therapeutic use
EP1742616B1 (en) Sustained-release microspheres and methods of making and using same
JP5712485B2 (en) Microparticles and pharmaceutical compositions thereof
US20080145432A1 (en) Fine Particle and Pharmaceutical Preparation
EP1864653A2 (en) Nanoparticles of chitosan and polyethyleneglycol as a system for the administration of biologically-active molecules
EP2308473A1 (en) Pharmaceutical composition containing surface-coated microparticles
EP2462896A1 (en) Method for the preparation of controlled release formulations
WO2004084819A2 (en) Poly(acryloyl-hydroxyethyl starch)-plga composite microspheres

Legal Events

Date Code Title Description
AS Assignment

Owner name: SILICON VALLEY BANK, CALIFORNIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:PR PHARMACEUTICALS, INC.;REEL/FRAME:020353/0884

Effective date: 20080114

Owner name: SILICON VALLEY BANK,CALIFORNIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:PR PHARMACEUTICALS, INC.;REEL/FRAME:020353/0884

Effective date: 20080114

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: PR PHARMACEUTICALS INC., COLORADO

Free format text: RELEASE;ASSIGNOR:SILICON VALLEY BANK;REEL/FRAME:021794/0979

Effective date: 20081105

AS Assignment

Owner name: PR PHARMACEUTICALS, INC., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BROOKWOOD PHARMACEUTICALS, INC.;REEL/FRAME:021861/0519

Effective date: 20081104

AS Assignment

Owner name: BROOKWOOD PHARMACEUTICALS, INC., ALABAMA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR AND ASSIGNEE PREVIOUSLY RECORDED ON REEL 021861 FRAME 0519;ASSIGNOR:PR PHARMACEUTICALS, INC.;REEL/FRAME:021876/0528

Effective date: 20081104

Owner name: BROOKWOOD PHARMACEUTICALS, INC., ALABAMA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR AND;ASSIGNOR:PR PHARMACEUTICALS, INC.;REEL/FRAME:021876/0528

Effective date: 20081104

AS Assignment

Owner name: BROOKWOOD PHARMACEUTICALS, INC., ALABAMA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NUMBER 60/489401 AND TITLE PREVIOUSLY RECORDED ON REEL 021876 FRAME 0528;ASSIGNOR:PR PHARMACEUTICALS, INC.;REEL/FRAME:023018/0114

Effective date: 20081104

Owner name: BROOKWOOD PHARMACEUTICALS, INC., ALABAMA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NUMBER;ASSIGNOR:PR PHARMACEUTICALS, INC.;REEL/FRAME:023018/0114

Effective date: 20081104